Abivax S.A. Overview
Pro stress-test →Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. The company is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases.
Strategic Profile
Pro stress-test →Phase 3 obefazimod maintenance data was released in early June 2026, causing significant stock volatility as traders reset expectations. The company raised approximately $400 million in a public offering (July 2025), demonstrating investor confidence in advancing development programs.
Competitive Landscape
Pro stress-test →Abivax competes in the crowded inflammatory bowel disease (IBD) therapeutic space against established biologics (TNF inhibitors, integrin antagonists, JAK inhibitors) and emerging small-molecule competitors. The company's differentiated miR-124 mechanism positions it as an alternative to conventional immunosuppressive approaches, but approval will depend on Phase 3 efficacy and safety profile relative to standard-of-care treatments.
Industry Context
Abivax S.A. operates in Biopharmaceuticals (Inflammatory Bowel Disease / Immunology).
Key facts
Founded: 2012 · Headquarters: Paris, France · Employees: N/A · Revenue: $0 · Market cap: N/A